TabsDetailsBasic DetailsDate Posted: Tuesday, April 3, 2018Status: CompleteMedical Product: fidaxomicin, metronidazole, vancomycinHealth Outcome(s): clostridium difficileDescription: These reports estimate the rate of hospital re-admission with Clostridium difficile (C. difficile) infection (identified using International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 008.45) following treatment with oral vancomycin, fidaxomicin, or metronidazole. Data from January 1, 2000 to December 31, 2012 from 18 Data Partners contributing to the Mini-Sentinel Distributed Database (MSDD) were utilized for the two reports that encompass this request. This request was distributed to Data Partners on August 27, 2013. Report 1 contains results from the first run, which has a query period of May 1, 2011 to December 31, 2012. Report 2 has a query period of January 1, 2000 to December 31, 2012. Read More Deliverables (2)Mini-Sentinel Modular Program Report: Clostridium difficile Infection Following Use of Vancomycin, Fidaxomicin, or Metronidzaole, Report 1Mini-Sentinel Modular Program Report: Clostridium difficile Infection Following Use of Vancomycin, Fidaxomicin, or Metronidzaole, Report 2Additional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2000 - December 31, 2012Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Mini-Sentinel Distributed Database (MSDD)